3-methoxytyramine has been researched along with Paraganglioma, Gangliocytic in 28 studies
3-methoxytyramine: RN given refers to parent cpd
3-methoxytyramine : A monomethoxybenzene that is dopamine in which the hydroxy group at position 3 is replaced by a methoxy group. It is a metabolite of the neurotransmitter dopamine and considered a potential biomarker of pheochromocytomas and paragangliomas.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Measurements of plasma free metanephrines (MNs), including MN and normetanephrine, provide high sensitivity and specificity for the diagnosis of pheochromocytoma and paraganglioma (PPGL)." | 8.12 | Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy. ( Gao, Y; Guo, X; Li, X; Li, Y; Liu, L; Song, Z; Wang, T; Xie, W; Zhang, J, 2022) |
| "Accurate diagnosis of pheochromocytoma and paraganglioma (PPGLs) is highly dependent on the detection of metanephrines and catecholamines." | 8.02 | Study of stability and interference for catecholamines and metanephrines, 3-methoxytyramine: key point of an accurate diagnosis for pheochromocytoma and paraganglioma. ( Cong, H; Gao, X; Guo, Y; Shi, X; Sun, N; Wang, K; Xie, L; Zhang, W; Zhou, Z, 2021) |
| " This study assessed whether urinary-free normetanephrine, metanephrine and methoxytyramine in overnight/first-morning urine collections might offer an alternative to measurements in 24-h collections or plasma for diagnosis of pheochromocytoma and paraganglioma (PPGL)." | 7.96 | Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option? ( Bursztyn, M; Conrad, C; Constantinescu, G; Därr, R; Eisenhofer, G; Fliedner, S; Kaden, D; Langton, K; Lenders, JWM; Pamporaki, C; Peitzsch, M; Prejbisz, A; Sinnott, RO, 2020) |
| "The 24 h urinary-fractionated metanephrine (MN) and normetanephrine (NMN) are recommended as the preferred indicators for laboratory diagnosis of pheochromocytoma and paraganglioma (PPGL)." | 7.96 | Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma. ( Cong, H; Dai, S; Gao, X; Shi, X; Wang, K; Zhang, W; Zhou, Z, 2020) |
| "In patients with phaeochromocytomas or paragangliomas (PPGLs), 24-h urine collections for metanephrines (uMNs) are cumbersome." | 7.96 | Random 'spot' urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas. ( Grossman, AB; Isidori, AM; Jafar-Mohammadi, B; James, T; Maunsell, Z; May, CJH; Sbardella, E; Shine, B; Tadman, M, 2020) |
| "Detection of normetanephrine (NMN), metanephrine (MN) and 3-methoxytyramine (3-MT) could be used to diagnose pheochromocytomas and paragangliomas (PPGLs)." | 7.96 | Detection of spot urinary free metanephrines and 3-methoxytyramine with internal reference correction for the diagnosis of pheochromocytomas and paragangliomas. ( Chen, H; Ding, M; Luo, C; Wang, H; Zhang, X; Zhen, Q; Zou, W, 2020) |
| "Plasma free metanephrines are commonly used for diagnosis of pheochromocytoma and paraganglioma (PPGLs), but can also provide other information." | 7.96 | Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. ( Bechmann, N; Beuschlein, F; Calsina, B; Constantinescu, G; Deutschbein, T; Eisenhofer, G; Fankhauser, M; Fassnacht, M; Fliedner, S; Langton, K; Lenders, JWM; Monteagudo, M; Nölting, S; Pamporaki, C; Peitzsch, M; Prejbisz, A; Robledo, M; Stell, A; Timmers, HJLM, 2020) |
| "Measurements of plasma methoxytyramine, the O-methylated dopamine metabolite, are useful for detecting rare dopamine-producing pheochromocytomas and paragangliomas (PPGLs) and head and neck paragangliomas (HNPGLs), but utility for screening beyond that achieved using standard measurements of normetanephrine and metanephrine is unclear." | 7.85 | Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. ( Beuschlein, F; Brugger, C; Eisenhofer, G; Fassnacht, M; Fliedner, S; Gudziol, V; Hanus, K; Januszewicz, A; Langton, K; Lenders, JWM; Pamporaki, C; Peitzsch, M; Prejbisz, A; Rao, D; Stell, A; Timmers, HJLM, 2017) |
| "This work discusses the clinical performance of deconjugated metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3MT) determined in the basal first morning urine using a chromatographic method with electrochemical detection for the clinical diagnosis of pheochromocytoma (PHEO) and paraganglioma (PGL)." | 7.81 | Deconjugated urinary metanephrine, normetanephrine and 3-methoxytyramine in laboratory diagnosis of pheochromocytoma and paraganglioma. ( Bešťák, J; Bílek, R; Dušková, J; Michalský, D; Novák, K; Vlček, P; Widimský, J; Zelinka, T, 2015) |
| "Measurements of plasma metanephrines and methoxytyramine provide a sensitive test for diagnosis of pheochromocytoma/paraganglioma." | 4.84 | False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade. ( Biemann, R; Eisenhofer, G; Pamporaki, C; Peitzsch, M; Rayes, N; Rohm, S; Sabri, O; Sandner, B; Schürfeld, R; Tönjes, A, 2024) |
| "Measurements of plasma free metanephrines (MNs), including MN and normetanephrine, provide high sensitivity and specificity for the diagnosis of pheochromocytoma and paraganglioma (PPGL)." | 4.12 | Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy. ( Gao, Y; Guo, X; Li, X; Li, Y; Liu, L; Song, Z; Wang, T; Xie, W; Zhang, J, 2022) |
| "Accurate diagnosis of pheochromocytoma and paraganglioma (PPGLs) is highly dependent on the detection of metanephrines and catecholamines." | 4.02 | Study of stability and interference for catecholamines and metanephrines, 3-methoxytyramine: key point of an accurate diagnosis for pheochromocytoma and paraganglioma. ( Cong, H; Gao, X; Guo, Y; Shi, X; Sun, N; Wang, K; Xie, L; Zhang, W; Zhou, Z, 2021) |
| " This study assessed whether urinary-free normetanephrine, metanephrine and methoxytyramine in overnight/first-morning urine collections might offer an alternative to measurements in 24-h collections or plasma for diagnosis of pheochromocytoma and paraganglioma (PPGL)." | 3.96 | Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option? ( Bursztyn, M; Conrad, C; Constantinescu, G; Därr, R; Eisenhofer, G; Fliedner, S; Kaden, D; Langton, K; Lenders, JWM; Pamporaki, C; Peitzsch, M; Prejbisz, A; Sinnott, RO, 2020) |
| "The 24 h urinary-fractionated metanephrine (MN) and normetanephrine (NMN) are recommended as the preferred indicators for laboratory diagnosis of pheochromocytoma and paraganglioma (PPGL)." | 3.96 | Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma. ( Cong, H; Dai, S; Gao, X; Shi, X; Wang, K; Zhang, W; Zhou, Z, 2020) |
| "In patients with phaeochromocytomas or paragangliomas (PPGLs), 24-h urine collections for metanephrines (uMNs) are cumbersome." | 3.96 | Random 'spot' urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas. ( Grossman, AB; Isidori, AM; Jafar-Mohammadi, B; James, T; Maunsell, Z; May, CJH; Sbardella, E; Shine, B; Tadman, M, 2020) |
| "Detection of normetanephrine (NMN), metanephrine (MN) and 3-methoxytyramine (3-MT) could be used to diagnose pheochromocytomas and paragangliomas (PPGLs)." | 3.96 | Detection of spot urinary free metanephrines and 3-methoxytyramine with internal reference correction for the diagnosis of pheochromocytomas and paragangliomas. ( Chen, H; Ding, M; Luo, C; Wang, H; Zhang, X; Zhen, Q; Zou, W, 2020) |
| "Plasma free metanephrines are commonly used for diagnosis of pheochromocytoma and paraganglioma (PPGLs), but can also provide other information." | 3.96 | Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. ( Bechmann, N; Beuschlein, F; Calsina, B; Constantinescu, G; Deutschbein, T; Eisenhofer, G; Fankhauser, M; Fassnacht, M; Fliedner, S; Langton, K; Lenders, JWM; Monteagudo, M; Nölting, S; Pamporaki, C; Peitzsch, M; Prejbisz, A; Robledo, M; Stell, A; Timmers, HJLM, 2020) |
| "Measurements of plasma or urinary metanephrines are recommended for diagnosis of pheochromocytoma and paraganglioma (PPGL)." | 3.88 | Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated ( Beuschlein, F; Deutschbein, T; Eisenhofer, G; Fassnacht, M; Fliedner, S; Januszewicz, A; Langton, K; Lenders, JWM; Masjkur, J; Megerle, F; Pamporaki, C; Pęczkowska, M; Peitzsch, M; Prejbisz, A; Rogowski-Lehmann, N; Sinnott, R; Timmers, HJLM; Tsourdi, E, 2018) |
| "Measurements of plasma methoxytyramine, the O-methylated dopamine metabolite, are useful for detecting rare dopamine-producing pheochromocytomas and paragangliomas (PPGLs) and head and neck paragangliomas (HNPGLs), but utility for screening beyond that achieved using standard measurements of normetanephrine and metanephrine is unclear." | 3.85 | Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma. ( Beuschlein, F; Brugger, C; Eisenhofer, G; Fassnacht, M; Fliedner, S; Gudziol, V; Hanus, K; Januszewicz, A; Langton, K; Lenders, JWM; Pamporaki, C; Peitzsch, M; Prejbisz, A; Rao, D; Stell, A; Timmers, HJLM, 2017) |
| "This work discusses the clinical performance of deconjugated metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3MT) determined in the basal first morning urine using a chromatographic method with electrochemical detection for the clinical diagnosis of pheochromocytoma (PHEO) and paraganglioma (PGL)." | 3.81 | Deconjugated urinary metanephrine, normetanephrine and 3-methoxytyramine in laboratory diagnosis of pheochromocytoma and paraganglioma. ( Bešťák, J; Bílek, R; Dušková, J; Michalský, D; Novák, K; Vlček, P; Widimský, J; Zelinka, T, 2015) |
| "Measurements of plasma normetanephrine (NMN) and metanephrine (MN) provide a sensitive test for diagnosis of phaeochromocytomas and paragangliomas (PPGLs), but do not allow detection of dopamine-producing tumours." | 3.79 | Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. ( Arlt, W; Beuschlein, F; Eisenhofer, G; Januszewicz, A; Kroiß, M; Peitzsch, M; Prejbisz, A; Siegert, G, 2013) |
| "A substantial number of patients with head and neck paragangliomas (HNPGLs) have biochemically active tumors, evidenced by increased urinary excretion of catecholamines and metabolites, including 3-methoxytyramine (3MT)." | 3.79 | Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. ( Brookman, D; Corssmit, EP; de Jong, WH; Kema, IP; Romijn, JA; van Duinen, N, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.57) | 29.6817 |
| 2010's | 14 (50.00) | 24.3611 |
| 2020's | 13 (46.43) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, L | 1 |
| Xie, W | 1 |
| Song, Z | 1 |
| Wang, T | 1 |
| Li, X | 1 |
| Gao, Y | 1 |
| Li, Y | 1 |
| Zhang, J | 1 |
| Guo, X | 1 |
| Wang, K | 3 |
| Gao, X | 2 |
| Zhang, W | 2 |
| Sun, N | 1 |
| Xie, L | 1 |
| Cong, H | 2 |
| Guo, Y | 1 |
| Shi, X | 2 |
| Zhou, Z | 2 |
| Richter, S | 1 |
| Qiu, B | 1 |
| Ghering, M | 1 |
| Kunath, C | 3 |
| Constantinescu, G | 4 |
| Luths, C | 1 |
| Pamporaki, C | 8 |
| Bechmann, N | 2 |
| Meuter, L | 2 |
| Kwapiszewska, A | 1 |
| Deutschbein, T | 3 |
| Nölting, S | 3 |
| Peitzsch, M | 11 |
| Robledo, M | 3 |
| Prejbisz, A | 9 |
| Pacak, K | 4 |
| Gudziol, V | 2 |
| Timmers, HJLM | 5 |
| Eisenhofer, G | 14 |
| Berends, AMA | 1 |
| Filippatos, A | 1 |
| Prodanov, T | 1 |
| Beuschlein, F | 6 |
| Fassnacht, M | 5 |
| Abhyankar, K | 1 |
| de Haas, RJ | 1 |
| Remde, H | 1 |
| Bornstein, SR | 3 |
| Januszewicz, A | 6 |
| Lenders, JWM | 6 |
| Kerstens, MN | 1 |
| Schürfeld, R | 1 |
| Rayes, N | 1 |
| Sabri, O | 1 |
| Rohm, S | 1 |
| Biemann, R | 1 |
| Sandner, B | 1 |
| Tönjes, A | 1 |
| Kaden, D | 1 |
| Langton, K | 4 |
| Conrad, C | 1 |
| Fliedner, S | 4 |
| Sinnott, RO | 1 |
| Därr, R | 1 |
| Bursztyn, M | 1 |
| Dai, S | 1 |
| Sbardella, E | 1 |
| Maunsell, Z | 1 |
| May, CJH | 1 |
| Tadman, M | 1 |
| James, T | 1 |
| Jafar-Mohammadi, B | 1 |
| Isidori, AM | 1 |
| Grossman, AB | 1 |
| Shine, B | 1 |
| Wang, H | 1 |
| Zhang, X | 1 |
| Zhen, Q | 1 |
| Zou, W | 1 |
| Chen, H | 1 |
| Luo, C | 1 |
| Ding, M | 1 |
| Calsina, B | 1 |
| Monteagudo, M | 1 |
| Fankhauser, M | 1 |
| Stell, A | 3 |
| Jian, M | 1 |
| Huang, H | 1 |
| Li, K | 1 |
| Chuan, L | 1 |
| Li, L | 1 |
| Jiang, L | 1 |
| Ortiz-Temprado, A | 1 |
| Martínez-Figueras, L | 1 |
| Montero-Domínguez, C | 1 |
| Małecki, R | 1 |
| Pistrosch, F | 1 |
| Bishoff, S | 1 |
| Mueller, P | 1 |
| Meyer, I | 1 |
| Reimann, D | 1 |
| Hanus, K | 2 |
| Parmentier, S | 1 |
| Passauer, J | 1 |
| Rao, D | 1 |
| Brugger, C | 1 |
| Masjkur, J | 1 |
| Rogowski-Lehmann, N | 1 |
| Tsourdi, E | 1 |
| Pęczkowska, M | 1 |
| Megerle, F | 1 |
| Sinnott, R | 1 |
| Mangelis, A | 1 |
| Huebner, A | 1 |
| Chtioui, H | 1 |
| Sadowski, SM | 1 |
| Winzeler, B | 1 |
| Tschopp, O | 1 |
| Grouzmann, E | 1 |
| Abid, K | 1 |
| Kroiß, M | 1 |
| Arlt, W | 1 |
| Siegert, G | 3 |
| van Duinen, N | 2 |
| Corssmit, EP | 2 |
| de Jong, WH | 1 |
| Brookman, D | 1 |
| Kema, IP | 3 |
| Romijn, JA | 2 |
| Brown, S | 1 |
| Pelzel, D | 1 |
| Lattke, P | 1 |
| Glöckner, S | 1 |
| Reichmann, H | 1 |
| van Berkel, A | 1 |
| Lenders, JW | 2 |
| Timmers, HJ | 2 |
| Bílek, R | 1 |
| Zelinka, T | 1 |
| Vlček, P | 1 |
| Dušková, J | 1 |
| Michalský, D | 1 |
| Novák, K | 1 |
| Bešťák, J | 1 |
| Widimský, J | 1 |
| Patin, F | 1 |
| Crinière, L | 1 |
| Francia, T | 1 |
| Kassem, S | 1 |
| Pierre, P | 1 |
| Bruno, C | 1 |
| Vayne, C | 1 |
| Vourc'h, P | 1 |
| Benz-de Bretagne, I | 1 |
| Andres, CR | 1 |
| Blasco, H | 1 |
| Steenvoorden, D | 1 |
| Jansen, JC | 1 |
| Vriends, AH | 1 |
| Bayley, JP | 1 |
| Smit, JW | 1 |
| Van Der Horst-Schrivers, AN | 1 |
| Osinga, TE | 1 |
| Van Der Laan, BF | 1 |
| Dullaart, RP | 1 |
| Friberg, P | 1 |
| Milosevic, D | 1 |
| Mannelli, M | 1 |
| Linehan, WM | 1 |
| Adams, K | 1 |
| Goldstein, DS | 1 |
| Sullivan, P | 1 |
| Csako, G | 1 |
| Brouwers, FM | 1 |
| Lai, EW | 1 |
| Adams, KT | 1 |
2 reviews available for 3-methoxytyramine and Paraganglioma, Gangliocytic
| Article | Year |
|---|---|
Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Biomarkers, Tumor; Catecholamines; Dopamine; False Negative Reaction | 2014 |
Laboratory evaluation of pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Clinical Laboratory Techniques; Dopamine; Humans; Metanephrine; Normetaneph | 2014 |
1 trial available for 3-methoxytyramine and Paraganglioma, Gangliocytic
| Article | Year |
|---|---|
Optimized procedures for testing plasma metanephrines in patients on hemodialysis.
Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Blood Chemical Analysis; Blood Specimen Collection | 2021 |
25 other studies available for 3-methoxytyramine and Paraganglioma, Gangliocytic
| Article | Year |
|---|---|
Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy.
Topics: Adrenal Gland Neoplasms; Chromogranin A; Dopamine; Humans; Metanephrine; Paraganglioma; Pheochromocy | 2022 |
Study of stability and interference for catecholamines and metanephrines, 3-methoxytyramine: key point of an accurate diagnosis for pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Anticoagulants; Catecholamines; Dopamine; Epinephrine; Hemoglobins; Humans; | 2021 |
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine.
Topics: Catecholamines; Dopamine; Female; Head and Neck Neoplasms; Humans; Male; Mutation; Normetanephrine; | 2022 |
Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.
Topics: Adrenal Gland Neoplasms; Cross-Sectional Studies; Humans; Machine Learning; Paraganglioma; Pheochrom | 2023 |
False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade.
Topics: Adrenal Gland Neoplasms; Antidepressive Agents, Tricyclic; Humans; Metanephrine; Norepinephrine; Nor | 2024 |
Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Biomarkers; Dopamine; Female; H | 2020 |
Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Chromatography, Liquid; Dopamine; Female; Humans; Male; Metanephrine; Norme | 2020 |
Random 'spot' urinary metanephrines compared with 24-h-urinary and plasma results in phaeochromocytomas and paragangliomas.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Age Factors; Aged; Aged, 80 and over; Area Under Curve; | 2020 |
Detection of spot urinary free metanephrines and 3-methoxytyramine with internal reference correction for the diagnosis of pheochromocytomas and paragangliomas.
Topics: Adrenal Gland Neoplasms; Chromatography, High Pressure Liquid; Cohort Studies; Dopamine; Humans; Lim | 2020 |
Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Dopamine; Fe | 2020 |
A 3-min UPLC-MS/MS method for the simultaneous determination of plasma catecholamines and their metabolites: Method verification and diagnostic efficiency.
Topics: Adrenal Gland Neoplasms; Calibration; Catecholamines; Chromatography, Liquid; Dopamine; Female; Huma | 2021 |
3-methoxytyramine secreting cervical paraganglioma.
Topics: Dopamine; Humans; Paraganglioma | 2021 |
Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Biomarkers; Child; Dopamine; Fe | 2017 |
Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Chromaffin Cells; Dopamine; Fem | 2018 |
Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy.
Topics: Adolescent; Adrenal Gland Neoplasms; Aging; Blood Chemical Analysis; Catecholamines; Child; Child, P | 2019 |
High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy?
Topics: Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Dopamine; Dopam | 2019 |
Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Blood Chemical Analysis; Chromatography, High Pressure Liquid; | 2013 |
Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites.
Topics: Adolescent; Adult; Aged; Algorithms; Biomarkers; Catecholamines; Cohort Studies; Cross-Sectional Stu | 2013 |
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Topics: Aged; Aged, 80 and over; Chromatography, Liquid; Dopamine; Epinephrine; Female; Humans; Levodopa; Ma | 2014 |
Deconjugated urinary metanephrine, normetanephrine and 3-methoxytyramine in laboratory diagnosis of pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Biomarkers; Chromatography, High Pressure Liquid; Clinical Lab | 2015 |
Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas.
Topics: Adrenal Gland Neoplasms; Dopamine; Humans; Paraganglioma; Pheochromocytoma; Retrospective Studies | 2016 |
Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas.
Topics: 3-Iodobenzylguanidine; Catecholamines; Cross-Sectional Studies; Dopamine; Female; Head and Neck Neop | 2010 |
Dopamine excess in patients with head and neck paragangliomas.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dopamine; Epinephrine; Female; Head and Neck Neoplas | 2010 |
Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Topics: Adrenal Gland Neoplasms; Adult; Biomarkers, Tumor; Dopamine; Female; Humans; Male; Middle Aged; Muta | 2012 |
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.
Topics: Adrenal Gland Neoplasms; Adult; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Middle Aged; | 2005 |